Mission statement
TheraVectys is a French biotechnology company located in the Pasteur Institute (Paris).
Based on the breakthrough DNA Flap lentiviral technology, we develop a new generation of vaccines against major health threats, such as AIDS, Hepatitis B&C, Tuberculosis, Malaria and cancer…
Background
TheraVectys has been founded by Dr Pierre Charneau (current CEO and CSO) who is also the Director of the Molecular Virology and Vectorology (VMV) research unit of the Pasteur Institute in Paris. TheraVectys Research and Development is based on:
- 15 years of pre-clinical work led by the VMV laboratory
- A strong collaborative research between VMV and TheraVectys.